InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.755 0.02 (2.72%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$360 Quarterly Cashflow Report 30 Jan 2019 10:11AM $1.110 $0.755 fallen by 31.98%
$360 Shareholder Update January 2019 17 Jan 2019 2:10PM $1.130 $0.755 fallen by 33.19%
$360 Becoming a substantial holder 14 Jan 2019 8:20AM $1.155 $0.755 fallen by 34.63%
$360 Response to ASX Aware Letter 7 Jan 2019 4:59PM $1.030 $0.755 fallen by 26.70%
$360 VivaGel condom receives final regulatory approval in Japan 2 Jan 2019 9:39AM $1.185 $0.755 fallen by 36.29%
$360 Change in Director's Interest Notice - P Turvey 28 Dec 2018 4:14PM $0.960 $0.755 fallen by 21.35%
$360 Change in Director's Interest Notice - J Fairley 28 Dec 2018 1:38PM $0.930 $0.755 fallen by 18.82%
$360 Change in Director's Interest Notice - R Thomas 28 Dec 2018 12:02PM $0.935 $0.755 fallen by 19.25%
$360 US FDA requests further data for VivaGel BV approval 27 Dec 2018 1:44PM $1.390 $0.755 fallen by 45.68%
$360 Ceasing to be a substantial holder 27 Dec 2018 8:23AM $1.400 $0.755 fallen by 46.07%
$360 US VivaGel BV licensed for A$142M milestones plus royalties 20 Dec 2018 9:30AM $1.355 $0.755 fallen by 44.28%
$360 US patent granted for SPL7013 eye drops for conjunctivitis 12 Dec 2018 8:50AM $1.430 $0.755 fallen by 47.20%
$360 Change in Director's Interest Notice - J Fairley 11 Dec 2018 3:18PM $1.420 $0.755 fallen by 46.83%
$360 Appendix 3B 11 Dec 2018 3:14PM $1.420 $0.755 fallen by 46.83%
$360 Becoming a substantial holder 11 Dec 2018 8:21AM $1.415 $0.755 fallen by 46.64%
$360 AGM Results 29 Nov 2018 5:18PM $1.560 $0.755 fallen by 51.60%
$360 AGM - Chairman address and CEO presentation 29 Nov 2018 1:09PM $1.555 $0.755 fallen by 51.45%
$360 DEP products outperform in human pancreatic cancer model 16 Nov 2018 11:31AM $1.460 $0.755 fallen by 48.29%
$360 Appendix 3B 5 Nov 2018 12:54PM $1.590 $0.755 fallen by 52.52%
$360 Notice of General Meeting/Proxy Form 26 Oct 2018 1:44PM $1.435 $0.755 fallen by 47.39%
$360 Quarterly Cashflow Report 26 Oct 2018 12:24PM $1.465 $0.755 fallen by 48.46%
$360 Starpharma Investor Presentation for Citi Conference 17 Oct 2018 9:54AM $1.425 $0.755 fallen by 47.02%
$360 Ceasing to be a substantial holder 8 Oct 2018 8:21AM $1.580 $0.755 fallen by 52.22%
$360 Change in Director's Interest Notice - J Fairley 5 Oct 2018 9:57AM $1.555 $0.755 fallen by 51.45%
$360 Appendix 3B 5 Oct 2018 9:53AM $1.555 $0.755 fallen by 51.45%

476 - 500 of 884 results

Page 20 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.